PharmTech Weekly Roundup–March 13, 2026

Welcome back to the PharmTech Weekly Roundup! I’m Susan Haigney, lead editor of PharmTech.

This week, the industry experienced accelerated digital transformation, regulatory evolution, and a strategic shift toward complex, patient-centric modalities. Across recent developments, we see a clear industry theme: the integration of real-time data and predictive tools—from the FDA’s new adverse event surveillance systems to advanced filling platforms—is being leveraged to reduce manufacturing risks and streamline the path from clinical development to commercial supply. Simultaneously, leadership transitions at FDA could impact long-term regulatory consistency and submission strategies.

In US regulatory news, FDA Commissioner Marty Makary announced that the director of the Center for Biologics Evaluation and Research, CBER, Dr. Vinay Prasad, will be exiting the agency in April. This is Prasad’s second resignation from the agency. He previously left after public criticism but was then reinstated. These frequent leadership changes at FDA may create a volatile regulatory environment that could lead to the reassessment of established submission strategies and clinical evidence expectations.

A New Adverse Event Monitoring System was launched by FDA this week. It is a unified platform that consolidates seven fragmented databases into a single dashboard providing manufacturers with real-time access to population-level safety signals. Historical adverse event data will be migrated to the new system, which will contain real-time adverse event reports for all FDA-regulated products by the end of May 2026.

In drug approval news, the FDA’s approval of leucovorin for an ultra-rare genetic folate deficiency establishes a significant precedent for using real-world and mechanistic evidence to clear the regulatory bar when randomized clinical trials are impractical.

In Europe, the European Commission has approved a 2 mg/kg every-four-weeks dosing regimen for Elfabrio, offering a significant reduction in cumulative treatment burden for stable adults with Fabry disease.

In patient access news, SteinCares and Shilpa Biologicals have entered a licensing agreement to expand access to cost-effective biosimilars in Latin America by pairing local market expertise with established biologics manufacturing capabilities.

At INTERPHEX this year in New York City, Groninger will be debuting a formalized "Lifecycle Solutions" service structure and a high-throughput ready-to-use filling platform designed to handle syringes, vials, and cartridges on a single configuration to improve production continuity,. The show is taking place at the Javits Center from April 21 through 23.

And INTERPHEX Week Tokyo 2026, which is happening May 20 through May 22, announced it will host 320 sessions focusing on manufacturing excellence, digital transformation, and the use of predictive tools to reduce technical-transfer risks and accelerate launch readiness.

Check out PharmTech.com for some of our latest technical articles. Contributing editor Cynthia Challener interviewed Tim Heffernan, PhD, vice president and head of the Therapeutics Discovery Division at The University of Texas MD Anderson Cancer Center about the shift to complex oncology modalities. The oncology sector is rapidly moving toward precision-driven, complex modalities such as next-generation antibody-drug conjugates, radioligand therapies, and multispecific antibodies to enhance tumor selectivity and overcome the immunosuppressive microenvironment.

A peer-reviewed study by authors from STERIS demonstrates that using Raman spectroscopy for identification and a specific detergent additive can effectively remove stubborn Type III magnetite rouge from stainless steel equipment without the need for costly mechanical polishing.

These updates highlight an industry that is becoming more technologically sophisticated while simultaneously managing complex regulatory and global supply chain shifts. Staying aligned with these trends is essential for maintaining compliance and operational efficiency. Visit PharmTech.com to read more about this week’s headlines.

Thank you for watching.